Common aspects of neuroplasticity, stress, mood disorders and mitochondrial functions

Activitas Nervosa Superior Rediviva

Volumn 52, Issue 1, 2010, Pages 3-20

  Fišar, Zdenek ^a   Hroudová, Jana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Antidepressive agents; Calcium; Glutamate; Hippocampus; Mitochondrial dysfunctions; Mood disorders; Mood stabilizers; Neuroplasticity; Stress; Synaptic plasticity

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPA RECEPTOR; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BUSPIRONE; CALCIUM; CARBAMAZEPINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLUCOCORTICOID; IPRONIAZID; MITOGEN ACTIVATED PROTEIN KINASE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PROTEIN BCL 2; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRIPLE REUPTAKE INHIBITOR; UNINDEXED DRUG; VALPROIC ACID;

ADRENERGIC SYSTEM; ALCOHOLISM; ALZHEIMER DISEASE; ANOREXIA NERVOSA; ANXIETY DISORDER; ARTICLE; ASTROCYTE; BIPOLAR DISORDER; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CELL FUNCTION; CHRONIC STRESS; COGNITIVE DEFECT; CUSHING SYNDROME; DEGENERATIVE DISEASE; DEMENTIA; DENDRITIC SPINE; DEPRESSION; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; EMOTION; ENERGY METABOLISM; EXECUTIVE FUNCTION; GENE EXPRESSION; GENE MUTATION; HIPPOCAMPUS; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; INFLAMMATION; LONG TERM POTENTIATION; MAJOR DEPRESSION; MEMORY DISORDER; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MITOCHONDRION; MOOD DISORDER; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NEUROTROPISM; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PARKINSON DISEASE; PREFRONTAL CORTEX; PREGNANCY; PRESYNAPTIC NERVE; PSYCHOSIS; PSYCHOTHERAPY; RESPIRATORY CHAIN; SCHIZOAFFECTIVE PSYCHOSIS; SEROTONINERGIC SYSTEM;

EID: 79751487130     PISSN: 1337933X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (178)

1. Aanhet Rot M, Mathew SJ, Charney DS (2009). Neurobiological mechanisms in major depressive disorder. CMAJ. 180(3): 305-313.
2. Abraham WC & Bear MF (1996). Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 19(4): 126-130.
3. Aguilera M, Arias B, Wichers M, Barrantes-Vidal N, Moya J, Villa H, et al (2009). Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med. 39(9): 1425-1432.
4. Armstrong JS (2007). Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol. 151(8): 1154-1165.
5. Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, Passarella S (2001). Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett. 497(1): 1-5.
6. Bagley J & Moghaddam B (1997). Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience. 77(1): 65-73.
7. Barco A, Bailey CH, Kandel ER (2006). Common molecular mechanisms in explicit and implicit memory. J Neurochem. 97(6): 1520-1533.
8. Beal MF (2009). Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 15(Suppl 3): S189-S194.
9. Ben-Shachar D & Karry R (2008). Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS ONE. 3(11): e3676.
10. Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, et al (2002). Monoamine depletion in unmedicated depressed subjects. Biol Psychiatry. 51(6): 469-473.
11. Berman SB, Pineda FJ, Hardwick JM (2008). Mitochondrial fission and fusion dynamics: the long and short of it. Cell Death Differ. 15(7): 1147-1152.
12. Billard JM (2008). D-serine signalling as a prominent determinant of neuronal-glial dialogue in the healthy and diseased brain. J Cell Mol Med. 12(5B): 1872-1884.
13. Bliss TV & Lømo T (1973). Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol. 232(2): 331-356.
14. Bremner JD (2006). Stress and brain atrophy. CNS Neurol Disord Drug Targets. 5(5): 503-512.
15. Bremner JD, Elzinga B, Schmahl C, Vermetten E (2008). Structural and functional plasticity of the human brain in posttraumatic stress disorder. Prog Brain Res. 167: 171-186.
16. Brunelle JK & Letai A (2009). Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 122(Pt 4): 437-441.
17. Campbell S, Marriott M, Nahmias C, MacQueen GM (2004). Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 161(4): 598-607.
18. Carlezon WA Jr, Duman RS, Nestler EJ (2005). The many faces of CREB. Trends Neurosci. 28(8): 436-445.
19. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al (2003). Influence of life stress on depression: moderation by a polymor-phism in the 5-HTT gene. Science. 301(5631): 386-389.
20. Castrén E (2005). Is mood chemistry? Nat Rev Neurosci. 6(3): 241-246.
21. Castrén E, Võikar V, Rantamäki T (2007). Role of neurotrophic factors in depression. Curr Opin Pharmacol. 7(1): 18-21.
22. Castrén E & Rantamäki T (2008). Neurotrophins in depression and antidepressant effects. Novartis Found Symp. 289: 43-52.
23. Castrén E & Rantamäki T (2010). Role of brain-derived neurotrophic factor in the aetiology of depression: implications for pharmacological treat-ment. CNS Drugs. 24(1): 1-7.
24. Chalmers S & Nicholls DG (2003). The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem. 278(21): 19062-19070.
25. Chaturvedi RK & Beal MF (2008). Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 1147: 395-412.
26. Chen AC, Shirayama Y, Shin KH, Neve RL, Duman RS (2001). Expression of the cAMP response element binding protein (CREB) in hippocam-pus produces an antidepressant effect. Biol Psychiatry. 49(9): 753-762.
27. Chevaleyre V, Takahashi KA, Castillo PE (2006). Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci. 29: 37-76.
28. Chevaleyre V, Heifets BD, Kaeser PS, Südhof TC, Castillo PE (2007). Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signal-ing and RIM1alpha. Neuron. 54(5): 801-812.
29. Chrousos GP (2009). Stress and disorders of the stress system. Nat Rev Endocrinol. 5(7): 374-381.
30. Chuang DM (2005). The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci. 1053: 195-204.
31. Citri A & Malenka RC (2008). Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology. 33(1): 18-41.
32. Cowen PJ (2008). Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci. 29(9): 433-436.
33. Culmsee C & Mattson MP (2005). p53 in neuronal apoptosis. Biochem Biophys Res Commun. 331(3): 761-777.
34. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, et al (1999). Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry. 46(2): 212-220.
35. Demaurex N & Distelhorst C (2003). Cell biology. Apoptosis - the calcium connection. Science. 300(5616): 65-77.
36. Derkach VA, Oh MC, Guire ES, Soderling TR (2007). Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 8(2): 101-113.
37. Draganski B & May A (2008). Training-induced structural changes in the adult human brain. Behav Brain Res. 192(1): 137-142.
38. Drzyzga LR, Marcinowska A, Obuchowicz E (2009). Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experi-mental studies. Brain Res Bull. 79(5): 248-257.
39. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry. 54(7): 597-606.
40. Duman RS & Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 59(12): 1116-1127.
41. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al (2008). In vitro assessment of mitochondrial dysfunction and cyto-toxicity of nefazodone, trazodone, and buspirone. Toxicol Sci. 103(2): 335-345.
42. Egashira T, Takayama F, Yamanaka Y (1996). Effects of long-term treatment with dicyclic, tricyclic, tetracyclic, and noncyclic antidepressant drugs on monoamine oxidase activity in mouse brain. Gen Pharmacol. 27(5): 773-778.
43. Einat H & Manji HK (2006). Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 59(12): 1160-1171.
44. Eisch AJ, Bolaños CA, de Wit J, Simonak RD, Pudiak CM, Barrot M, et al (2003). Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry. 54(10): 994-1005.
45. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, et al (1989). National Institute of Mental Health Treatment of Depression Col-laborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry. 46(11): 971-982.
46. Etkin A, Pittenger C, Polan HJ, Kandel ER (2005). Toward a neurobiology of psychotherapy: basic science and clinical applications. J Neuropsy-chiatry Clin Neurosci. 17(2): 145-158.
47. Fagervall I & Ross SB (1986). Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochem Pharmacol. 35(8): 1381-1387.
48. Fattal O, Budur K, Vaughan AJ, Franco K (2006). Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 47(1): 1-7.
49. Feinberg AP (2010). Genome-scale approaches to the epigenetics of common human disease. Virchows Arch. 456(1): 13-21.
50. Fišar Z & Raboch J (2008) Depression, antidepressants, and peripheral blood components. Neuroendocrinol Lett. 29(1): 17-28.
51. Fišar Z (2009). Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev. 2(1): 51-75.
52. Fišar Z & Hroudová J (2010). Intracellular signalling pathways and mood disorders. Folia Biol. 56, in press.
53. Fišar Z, Hroudová J, Raboch J (2010). Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuroendocrinol Lett. 31, in press.
54. Frey U & Morris RG (1997). Synaptic tagging and long-term potentiation. Nature. 385(6616): 533-536.
55. García-Junco-Clemente P, Linares-Clemente P, Fernández-Chacón R (2005). Active zones for presynaptic plasticity in the brain. Mol Psychiatry. 10(2): 185-200.
56. Genoux D & Montgomery JM (2007). Glutamate receptor plasticity at excitatory synapses in the brain. Clin Exp Pharmacol Physiol. 34(10): 1058-1063.
57. Giorgi C, De Stefani D, Bononi A, Rizzuto R, Pinton P (2009). Structural and functional link between the mitochondrial network and the endo-plasmic reticulum. Int J Biochem Cell Biol. 41(10): 1817-1827.
58. Gnerre C, Kosel M, Baumann P, Carrupt P-A, Testa B (2001). Interaction of psychotropic drugs with monoamine oxidase in rat brain. J Pharm Pharmacol. 53(8): 1125-1130.
59. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK (2004). Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry. 9(8): 734-755.
60. Gould TD & Manji HK (2005). Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 30(7): 1223-1237.
61. Gould TD, Dow ER, O'Donnell KC, Chen G, Manji HK (2007). Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway. CNS Neurol Disord Drug Targets. 6(3): 193-204.
62. Haddad JJ, Saadé NE, Safieh-Garabedian B (2002). Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis. J Neuroimmunol. 133(1-2): 1-19.
63. Hajek T, Kopecek M, Kozeny J, Gunde E, Alda M, Höschl C (2009). Amygdala volumes in mood disorders - meta-analysis of magnetic resonance volumetry studies. J Affect Disord. 115(3): 395-410.
64. Halassa MM & Haydon PG (2010). Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu Rev Physiol. 72: 335-355.
65. Heninger GR, Delgado PL, Charney DS (1996). The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry. 29(1): 2-11.
66. Hollenbeck PJ & Saxton WM (2005). The axonal transport of mitochondria. J Cell Sci. 118(Pt 23): 5411-5419.
67. Holt IJ (2010). Zen and the art of mitochondrial DNA maintenance. Trends Genet. 26(3): 103-109.
68. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, et al; European Federation of Neurological Societies; Movement Disor-der Society-European Section (2006). Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the Euro-pean Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 13(11): 1170-1185.
69. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, et al (1996). Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3ß in brain. Proc Natl Acad Sci USA. 93(7): 2719-2723.
70. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW, et al (2008). Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology. 55(5): 826-834.
71. Ikonomidou C & Turski L (1996). Neurodegenerative disorders: clues from glutamate and energy metabolism. Crit Rev Neurobiol. 10(2): 239-263.
72. Iosifescu DV & Renshaw PE (2003). 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioener-getic mechanism in depression? Harv Rev Psychiatry. 11(2): 51-63.
73. Jimerson DC, Post RM, Carman JS, van Kammen DP, Wood JH, Goodwin FK, et al (1979). CSF calcium: clinical correlates in affective illness and schizophrenia. Biol Psychiatry. 14(1): 37-51.
74. Johnson SL (2005). Life events in bipolar disorder: towards more specific models. Clin Psychol Rev. 25(8): 1008-1027.
75. Jou S-H, Chiu N-Y, Liu C-S (2009). Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med J. 32(4): 370-379.
76. Kasper S & McEwen BS (2008). Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs. 22(1): 15-26.
77. Kato T & Kato N (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2(3 Pt 1): 180-190.
78. Kato T, Ishiwata M, Mori K, Washizuka S, Tajima O, Akiyama T, et al (2003). Mechanisms of altered Ca2+ signalling in transformed lymphoblas-toid cells from patients with bipolar disorder. Int J Neuropsychopharmacol. 6(4): 379-389.
79. Kato T (2007). Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 21(1): 1-11.
80. Kato T, Kakiuchi C, Iwamoto K (2007). Comprehensive gene expression analysis in bipolar disorder. Can J Psychiatry. 52(12): 763-771.
81. Kato T (2008). Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 44(1): 92-102.
82. Kendler KS, Karkowski LM, Prescott CA (1999). Causal relationship between stressful life events and the onset of major depression. Am J Psy-chiatry. 156(6): 837-841.
83. Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, et al (2006) MAOA, maltreatment, and gene-environment interaction pre-dicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry. 11(10): 903-913.
84. Kirichok Y, Krapivinsky G, Clapham DE (2004). The mitochondrial calcium uniporter is a highly selective ion channel. Nature. 427(6972): 360-364.
85. Kitzlerová E & Anders M (2007). The role of some new factors in the pathophysiology of depression and cardiovascular disease: overview of re-cent research. Neuroendocrinol Lett. 28(6): 832-840.
86. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S (2004). Molecular evidence for mitochondrial dysfunction in bipolar disor-der. Arch Gen Psychiatry. 61(3): 300-308.
87. Kovaru H, Pav M, Kovaru F, Raboch J, Fiserova A (2009). Cell signalling in CNS and immune system in depression and during antidepressant treatment: focus on glial and natural killer cells. Neuroendocrinol Lett. 30(4): 421-428.
88. Kramlinger KG & Post RM (1996). Ultra-rapid and ultradian cycling in bipolar affective illness. Br J Psychiatry. 168(3): 314-323.
89. Krishnan V & Nestler EJ (2008). The molecular neurobiology of depression. Nature. 455(7215): 894-902.
90. Kronenberg G, Colla M, Endres M (2009). Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med. 9(3): 315-323.
91. Lambert PD, McGirr KM, Ely TD, Kilts CD, Kuhar MJ (1999). Chronic lithium treatment decreases neuronal activity in the nucleus accumbens and cingulate cortex of the rat. Neuropsychopharmacology. 21(2): 229-237.
92. Lee AL, Ogle WO, Sapolsky RM (2002). Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord. 4(2): 117-128.
93. Leonard BE (2007). Inflammation, depression and dementia: are they connected? Neurochem Res. 32(10): 1749-1756.
94. Leonard BE & Myint A (2009). The psychoneuroimmunology of depression. Hum Psychopharmacol. 24(3): 165-175.
95. Li Z, Okamoto K, Hayashi Y, Sheng M (2004). The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and syn-apses. Cell. 119(6): 873-887.
96. Lipton P (1999). Ischemic cell death in brain neurons. Physiol Rev. 79(4): 1431-1568.
97. Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, et al (2006). Stress-induced alterations in prefrontal cortical dendritic mor-phology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 26(30): 7870-7874.
98. López-León S, Janssens AC, González-Zuloeta Ladd AM, Del-Favero J, Claes SJ, Oostra BA, et al (2008). Meta-analyses of genetic studies on major depressive disorder. Mol Psychiatry. 13(8):772-785.
99. Lu B (2009). Mitochondrial dynamics and neurodegeneration. Curr Neurol Neurosci Rep. 9(3): 212-219.
100. Madrigal JLM, Olivenza R, Moro MA, Lizasoain I, Lorenzo P, Rodrigo J, et al (2001). Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology. 24(4): 420-429.
101. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al (2009). The inflammatory & neurodegenerative (I & ND) hypothesis of depres-sion: leads for future research and new drug developments in depression. Metab Brain Dis. 24(1): 27-53.
102. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, A Gray N, et al (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 53(8): 707-742.
103. Manoli I, Alesci S, Blackman MR, Su YA, Rennert OM, Chrousos GP (2007). Mitochondria as key components of the stress response. Trends Endocrinol Metab. 18(5): 190-198.
104. Marder E & Goaillard J-M (2006). Variability, compensation and homeostasis in neuron and network function. Nat Rev Neurosci. 7(7): 563-574.
105. Mathew SJ, Manji HK, Charney DS (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 33(9): 2080-2092.
106. Mattson MP, Keller JN, Begley JG (1998). Evidence for synaptic apoptosis. Exp Neurol. 153(1): 35-48.
107. Mattson MP, Gleichmann M, Cheng A (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron. 60(5): 748-766.
108. Maurer IC, Schippel P, Volz H-P (2009). Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord. 11(5): 515-522.
109. McBain CJ & Kauer JA (2009). Presynaptic plasticity: targeted control of inhibitory networks. Curr Opin Neurobiol. 19(3): 254-262.
110. McCormack JG, Halestrap AP, Denton RM (1990). Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev. 70(2): 391-425.
111. McEwen BS & Sapolsky RM (1995). Stress and cognitive function. Curr Opin Neurobiol. 5(2): 205-216.
112. McEwen BS (2007). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 87(3): 873-904.
113. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, et al (2010). The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry. 15(3): 237-249.
114. McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009). A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci. 34(1): 41-54.
115. Mendelsohn D, Riedel WJ, Sambeth A (2009). Effects of acute tryptophan depletion on memory, attention and executive functions: a systematic review. Neurosci Biobehav Rev. 33(6): 926-952.
116. Mesulam MM (1999). Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 24(3):521-529.
117. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al (2006). Elevated monoamine oxidase a levels in the brain: an explana-tion for the monoamine imbalance of major depression. Arch Gen Psychiatry. 63(11):1209-1216.
118. Mill J & Petronis A (2007). Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry. 12(9): 799-814.
119. Milne A, MacQueen GM, Yucel K, Soreni N, Hall GB (2009). Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. Neuroimage. 47(1): 36-41.
120. Miyashita T, Kubik S, Lewandowski G, Guzowski JF (2008). Networks of neurons, networks of genes: an integrated view of memory consolida-tion. Neurobiol Learn Mem. 89(3): 269-284.
121. Moghaddam B (2002). Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol Psychiatry. 51(10): 775-787.
122. Montgomery JM & Madison DV (2004). Discrete synaptic states define a major mechanism of synapse plasticity. Trends Neurosci. 27(12): 744-750.
123. Nelson SB & Turrigiano GG (2008). Strength through diversity. Neuron. 60(3): 477-482.
124. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron. 34(1): 13-25.
125. Nestler EJ & Carlezon WA Jr (2006). The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 59(12): 1151-1159.
126. Neustadt J & Pieczenik SR (2008). Medication-induced mitochondrial damage and disease. Mol Nutr Food Res. 52(7): 780-788.
127. Neves G, Cooke SF, Bliss TV (2008). Synaptic plasticity, memory and the hippocampus: a neural network approach to causality. Nat Rev Neuro-sci. 9(1): 65-75.
128. O'Dell TJ, Connor SA, Gelinas JN, Nguyen PV (2010). Viagra for your synapses: Enhancement of hippocampal long-term potentiation by activa-tion of beta-adrenergic receptors. Cell Signal. 22: 728-736.
129. Orth M & Schapira AH (2001). Mitochondria and degenerative disorders. Am J Med Genet. 106(1): 27-36.
130. Parpura V & Zorec R (2009). Gliotransmission: Exocytotic release from astrocytes. Brain Res Rev.;doi:10.1016/j.brairesrev.2009.11.008.
131. Pathak RU & Davey GP (2008). Complex I and energy thresholds in the brain. Biochim Biophys Acta. 1777(7-8): 777-782.
132. Paul IA & Skolnick P (2003). Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 1003:250-272.
133. Páv M, Kováru H, Fišerová A, Havrdová E, Lisá V (2008). Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. Physiol Res. 57(2): 151-164.
134. Perea G & Araque A (2009). GLIA modulates synaptic transmission. Brain Res Rev. doi:10.1016/j.brainresrev.2009.10.005
135. Pittenger C & Duman RS (2008). Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 33(1): 88-109.
136. Ponti G, Peretto P, Bonfanti L (2008). Genesis of neuronal and glial progenitors in the cerebellar cortex of peripuberal and adult rabbits. PLoS ONE. 3(6): e2366.
137. Quiroz JA, Gould TD, Manji HK (2004). Molecular effects of lithium. Mol Interv. 4(5): 259-272.
138. Quiroz JA, Gray NA, Kato T, Manji HK (2008). Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology. 33(11): 2551-2565.
139. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 6(3): 219-233.
140. Rao VR & Finkbeiner S (2007). NMDA and AMPA receptors: old channels, new tricks. TRENDS Neurosci. 30(6): 284-291.
141. Reyes E & Lisansky J (1984). Effects of tricyclic antidepressants on platelet monoamine oxidase activity. Clin Pharmacol Ther. 35(4): 531-534.
142. Rezin GT, Cardoso MR, Gonçalves CL, Scaini G, Fraga DB, Riegel RE, et al (2008). Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int. 53(6-8): 395-400.
143. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL (2009a). Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 34(6): 1021-1029.
144. Rezin GT, Gonçalves CL, Daufenbach JF, Fraga DB, Santos PM, Ferreira GK, et al (2009b). Acute administration of ketamine reverses the inhibi-tion of mitochondrial respiratory chain induced by chronic mild stress. Brain Res Bull. 79(6): 418-421.
145. Riederer P, Danielczyk W, Grünblatt E (2004). Monoamine oxidase-B inhibition in Alzheimer's disease. NeuroToxicology. 25(1-2): 271-277.
146. Rizzuto R & Pozzan T (2006). Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev. 86(1): 369-408.
147. Ruhé HG, Mason NS, Schene AH (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 12(4): 331-359.
148. Santo-Domingo J & Demaurex N (2010). Calcium uptake mechanisms of mitochondria. Biochim Biophys Acta., doi:10.1016/j.bbabio.2010.01.005
149. Sapolsky RM (1996). Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. Stress. 1(1): 1-19.
150. Sapolsky RM (2003). Stress and plasticity in the limbic system. Neurochem Res. 28(11): 1735-1742.
151. Sapolsky RM (2004). Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry. 56(3): 137-139.
152. Sas K, Robotka H, Toldi J, Vécsei L (2007). Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neu-rodegenerative disorders. J Neurol Sci. 257(1-2): 221-239.
153. Savitz J & Drevets WC (2009). Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev. 33(5): 699-771.
154. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B (2007). The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol. 293(1): C12-C21.
155. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, et al (2008). Mitochondrial involvement in psychiatric disorders. Ann Med. 40(4): 281-295.
156. Silva AJ, Zhou Y, Rogerson T, Shobe J, Balaji J (2009). Molecular and cellular approaches to memory allocation in neural circuits. Science. 326(5951): 391-395.
157. Stahl SM & Felker A (2008). Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 13(10): 855-870.
158. Stork C & Renshaw PF (2005). Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psy-chiatry. 10(10): 900-919.
159. Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X (2010). Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 1802(1): 135-142.
160. Sun X, Wang J-F, Tseng M, Young LT (2006). Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci. 31(3): 189-196.
161. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M (2006). Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev. 58(1): 115-134.
162. Tóth K & McBain CJ (2000). Target-specific expression of pre- and postsynaptic mechanisms. J Physiol. 525.1: 41-51.
163. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 9:519-525.
164. Turrigiano GG, Leslie KR, Desai NS, Rutherford LC, Nelson SB (1998). Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature. 391(6670): 892-896.
165. von Bohlen und Halbach O (2009). Structure and function of dendritic spines within the hippocampus. Ann Anat. 191(6): 518-531.
166. Wallace DC & Fan W (2010). Energetics, epigenetics, mitochondrial genetics. Mitochondrion. 10(1): 12-31.
167. Walsh C, Barrow S, Voronina S, Chvanov M, Petersen OH, Tepikin A (2009). Modulation of calcium signalling by mitochondria. Biochim Biophys Acta. 1787(11): 1374-1382.
168. Wang J-F (2007). Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can J Psy-chiatry. 52(12): 753-762.
169. Warner-Schmidt JL & Duman RS (2006). Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 16(3): 239-249.
170. Wojda U, Salinska E, Kuznicki J (2008). Calcium ions in neuronal degeneration. IUBMB Life. 60(9): 575-590.
171. 2+ exchanger and protein kinase C. J Cell Biol. 163(3): 511-523.
172. Yildiz-Yesiloglu A & Ankerst DP (2006). Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry. 30(6): 969-995.
173. Youdim MB & Bakhle YS (2006). Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol. 147(Suppl 1): S287-S296.
174. Youdim MB, Edmondson D, Tipton KF (2006). The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 7(4): 295-309.
175. Young JZ, Isiegas C, Abel T, Nguyen PV (2006). Metaplasticity of the late-phase of long-term potentiation: a critical role for protein kinase A in synaptic tagging. Eur J Neurosci. 23(7): 1784-1794.
176. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW (2005). Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology. 30(9): 1719-1723.
177. Zarate CA Jr, Singh J, Manji HK (2006a). Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 59(11): 1006-1020.
178. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al (2006b). A randomized trial of an N-methyl-D-aspartate an-tagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63(8): 856-864.